Protalix biotherapeutics, inc. (PLX)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
REVENUES

54,693

34,240

21,078

-

4,364

3,523

0

34,870

8,386

6,642

388

COMPANY'S SHARE IN COLLABORATION AGREEMENT

-

-

-

-

-

-

-

-446

-5,418

4,602

-

COST OF GOODS SOLD

10,895

9,302

15,231

8,398

730

630

0

8,144

1,525

4,383

3,575

GROSS PROFIT (LOSS)

-

-

-

-

3,634

2,893

0

26,280

1,443

6,861

-3,187

RESEARCH AND DEVELOPMENT EXPENSES

44,693

35,534

32,170

30,412

24,889

27,352

29,225

36,665

37,818

37,691

27,390

Less - grants

77

2,204

3,336

5,804

4,864

5,128

3,213

7,976

6,775

7,740

-

less - grants and reimbursements

-

-

-

-

-

-

-

-

-

-

5,752

RESEARCH AND DEVELOPMENT EXPENSES, NET

44,616

33,330

28,834

24,608

20,025

22,224

26,012

28,689

31,043

29,951

21,638

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

9,899

10,916

11,530

9,356

7,279

9,228

8,051

9,763

-

-

-

GENERAL AND ADMINISTRATIVE EXPENSES

-

-

-

-

-

-

-

-

6,931

6,876

7,144

OPERATING LOSS

-10,717

-19,308

-34,517

-33,163

-23,670

-28,559

-34,063

-12,172

-36,531

-29,966

-31,969

FINANCIAL EXPENSES

7,966

7,685

9,725

4,192

3,735

4,935

1,065

34

-

-

-

FINANCIAL INCOME

407

536

188

589

123

196

391

588

-

-

-

LOSS FROM CHANGE IN FAIR VALUE OF CONVERTIBLE NOTES EMBEDDED DERIVATIVE

0

0

-38,061

-6,473

0

-

-

-

-

-

-

LOSS ON EXTINGUISHMENT OF CONVERTIBLE NOTES

0

0

-1,325

14,063

0

-

-

-

-

-

-

FINANCIAL EXPENSES - NET

-7,559

-7,149

-48,923

3,987

-3,612

-4,739

-674

554

2

-

-

LOSS FROM CONTINUING OPERATIONS

-

-

-

-29,176

-27,282

-33,298

-34,737

-

-

-

-

LOSS FROM DISCONTINUED OPERATIONS

-

-

-

-189

85,319

3,355

6,947

-

-

-

-

FINANCIAL INCOME - NET

-

-

-

-

-

-

-

-

-

968

529

NET LOSS FOR THE YEAR

-18,276

-26,457

-83,440

-29,365

58,037

-29,943

-27,790

-11,618

-36,529

-28,998

-31,440

NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED

-1.23

-1.80

-6.37

-0.29

0.61

-0.32

-0.30

-0.13

-0.43

-0.36

0.41

Loss from continuing operations

-

-

-

-0.29

-0.29

-0.36

-0.38

-

-

-

-

Loss from discontinued operations

-

-

-

0.00

0.90

0.04

0.08

-

-

-

-

WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE-BASIC AND DILUTED

14,838

14,713

13,108

101,387

94,922

92,891

92,368

90,845

84,645

80,960

-

WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE of common stock, basic and diluted

-

-

-

-

-

-

-

-

-

-

76,942

Goods [Member]
REVENUES

15,866

8,978

19,242

9,199

-

-

-

-

-

-

-

License and R&D Services [Member]
REVENUES

38,827

25,262

1,836

-

-

-

-

-

-

-

-